Gyeonggi-do, South Korea

Mikyung Chang

This inventor holds 1 USPTO granted patent. Top assignee: Abl Bio Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mikyung Chang. Retrieved from https://idiyas.com/inventor/mikyung-chang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mikyung Chang: Innovator in Cancer Treatment

Introduction

Mikyung Chang is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development.

Latest Patents

Mikyung Chang holds a patent for an "Anti-BCMA antibody and use thereof." This invention provides an antibody or antigen-binding fragment that specifically binds to a B-cell maturation antigen (BCMA). The method of preparing this antibody and its applications are crucial for effectively preventing or treating cancers. He has 1 patent to his name.

Career Highlights

Mikyung Chang is associated with Abl Bio Inc., a company focused on developing innovative therapies. His work at Abl Bio Inc. emphasizes the importance of targeted cancer treatments, showcasing his commitment to advancing medical science.

Collaborations

Mikyung Chang collaborates with talented individuals such as Kyungjin Park and Hyejin Chung. Their combined expertise contributes to the success of their projects and enhances the research environment at Abl Bio Inc.

Conclusion

Mikyung Chang's contributions to cancer treatment through his patented innovations highlight his role as a leading inventor in the field. His work continues to inspire advancements in medical research and therapy development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…